Incidence and survival of hematological cancers among adults ages ≥75 years

Jessica L Krok-Schoen, James L Fisher, Julie A Stephens, Alice Mims, Sabarish Ayyappan, Jennifer A Woyach, Ashley E Rosko, Jessica L Krok-Schoen, James L Fisher, Julie A Stephens, Alice Mims, Sabarish Ayyappan, Jennifer A Woyach, Ashley E Rosko

Abstract

Evaluating population-based data of hematologic malignancies (HMs) in older adults provides prognostic information for this growing demographic. Incidence rates and one- and five-year relative survival rates were examined for specific HMs among adults ages ≥75 years using data from the Surveillance, Epidemiology and End Results (SEER) Program. Hematologic malignancy cases (Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), multiple myeloma (MM), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML)) were reported to one of 18 SEER registries. Recent average annual (2010-2014) incidence rates and incidence trends from 1973 to 2014 were examined for cases ages ≥75 years. One- and five-year relative cancer survival rates were examined for adults ages ≥75 years diagnosed 2007-2013, with follow-up into 2014. From 1973 to 2014, incidence rates increased for NHL, MM, and AML, decreased for HL, and remained relatively stable for ALL, CLL, and CML among adults ages ≥75 years. The highest one- and five-year relative survival rates were observed among adults with CLL ages 75-84 years (1 year: 91.8% (95% CI = 91.8-90.8)) and 5 years: 76.5% (95% CI = 74.2-78.6)). The lowest one- and five-year survival rates were observed among adults with AML ages 75-84 (1 year: 18.2% (95% CI = 74.2-78.6) and 5 years: 2.7% (95% CI = 2.0-3.6)). Survival for older adults ages ≥75 years with HMs is poor, particularly for acute leukemia. Understanding the heterogeneity in HM outcomes among older patients may help clinicians better address the hematological cancer burden and mortality in the aging population.

Keywords: Cancer; SEER Program; elderly; hematologic malignancies; older adults.

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
(A–G) Incidence of hematological cancers over time among adults ages

Figure 2

One‐year survival rates by disease…

Figure 2

One‐year survival rates by disease type among adults ages

Figure 2
One‐year survival rates by disease type among adults ages

Figure 3

Five‐year survival rates by disease…

Figure 3

Five‐year survival rates by disease type among adults ages

Figure 3
Five‐year survival rates by disease type among adults ages

Figure 4

(A–G) Kaplan‐Meier survival curves of…

Figure 4

(A–G) Kaplan‐Meier survival curves of hematological cancers among adults ages

Figure 4
(A–G) Kaplan‐Meier survival curves of hematological cancers among adults ages
Similar articles
Cited by
References
    1. Rodriguez‐Abreu, D. , Bordoni A., and Zucca E.. 2007. Epidemiology of hematological malignancies. Ann. Oncol. 18(Suppl. 1):i3–i8. - PubMed
    1. American Cancer Society . 2018. Cancer Facts & Figures, 2018. American Cancer Society, Atlanta, GA.
    1. Howlander, N. , Noone A., Krapcho M., Miller D., Bishop K., Kosary C., et al. 2017. SEER Cancer Statistics Review, 1975–2014. National Cancer Institute, Bethesda, MD: Available at https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site.
    1. Smith, B. D. , Smith G. L., Hurria A., Hortobagyi G. N., and Buchholz T. A.. 2009. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J. Clin. Oncol. 27:2758–2765. - PubMed
    1. American Cancer Society . 2017. Cancer Statistics Center. American Cancer Society, Atlanta, GA.
Show all 46 references
LinkOut - more resources
Full text links [x]
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Figure 2
Figure 2
One‐year survival rates by disease type among adults ages

Figure 3

Five‐year survival rates by disease…

Figure 3

Five‐year survival rates by disease type among adults ages

Figure 3
Five‐year survival rates by disease type among adults ages

Figure 4

(A–G) Kaplan‐Meier survival curves of…

Figure 4

(A–G) Kaplan‐Meier survival curves of hematological cancers among adults ages

Figure 4
(A–G) Kaplan‐Meier survival curves of hematological cancers among adults ages
Similar articles
Cited by
References
    1. Rodriguez‐Abreu, D. , Bordoni A., and Zucca E.. 2007. Epidemiology of hematological malignancies. Ann. Oncol. 18(Suppl. 1):i3–i8. - PubMed
    1. American Cancer Society . 2018. Cancer Facts & Figures, 2018. American Cancer Society, Atlanta, GA.
    1. Howlander, N. , Noone A., Krapcho M., Miller D., Bishop K., Kosary C., et al. 2017. SEER Cancer Statistics Review, 1975–2014. National Cancer Institute, Bethesda, MD: Available at https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site.
    1. Smith, B. D. , Smith G. L., Hurria A., Hortobagyi G. N., and Buchholz T. A.. 2009. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J. Clin. Oncol. 27:2758–2765. - PubMed
    1. American Cancer Society . 2017. Cancer Statistics Center. American Cancer Society, Atlanta, GA.
Show all 46 references
LinkOut - more resources
Full text links [x]
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Figure 3
Figure 3
Five‐year survival rates by disease type among adults ages

Figure 4

(A–G) Kaplan‐Meier survival curves of…

Figure 4

(A–G) Kaplan‐Meier survival curves of hematological cancers among adults ages

Figure 4
(A–G) Kaplan‐Meier survival curves of hematological cancers among adults ages
Similar articles
Cited by
References
    1. Rodriguez‐Abreu, D. , Bordoni A., and Zucca E.. 2007. Epidemiology of hematological malignancies. Ann. Oncol. 18(Suppl. 1):i3–i8. - PubMed
    1. American Cancer Society . 2018. Cancer Facts & Figures, 2018. American Cancer Society, Atlanta, GA.
    1. Howlander, N. , Noone A., Krapcho M., Miller D., Bishop K., Kosary C., et al. 2017. SEER Cancer Statistics Review, 1975–2014. National Cancer Institute, Bethesda, MD: Available at https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site.
    1. Smith, B. D. , Smith G. L., Hurria A., Hortobagyi G. N., and Buchholz T. A.. 2009. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J. Clin. Oncol. 27:2758–2765. - PubMed
    1. American Cancer Society . 2017. Cancer Statistics Center. American Cancer Society, Atlanta, GA.
Show all 46 references
LinkOut - more resources
Full text links [x]
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Figure 4
Figure 4
(A–G) Kaplan‐Meier survival curves of hematological cancers among adults ages

References

    1. Rodriguez‐Abreu, D. , Bordoni A., and Zucca E.. 2007. Epidemiology of hematological malignancies. Ann. Oncol. 18(Suppl. 1):i3–i8.
    1. American Cancer Society . 2018. Cancer Facts & Figures, 2018. American Cancer Society, Atlanta, GA.
    1. Howlander, N. , Noone A., Krapcho M., Miller D., Bishop K., Kosary C., et al. 2017. SEER Cancer Statistics Review, 1975–2014. National Cancer Institute, Bethesda, MD: Available at , based on November 2016 SEER data submission, posted to the SEER web site.
    1. Smith, B. D. , Smith G. L., Hurria A., Hortobagyi G. N., and Buchholz T. A.. 2009. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J. Clin. Oncol. 27:2758–2765.
    1. American Cancer Society . 2017. Cancer Statistics Center. American Cancer Society, Atlanta, GA.
    1. Surveillance E, and End Results (SEER) Program . 2017. Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute.
    1. Artz, A. S. 2012. From biology to clinical practice: aging and hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 18(1 Suppl):S40–S45.
    1. Appelbaum, F. R. , Gundacker H., Head D. R., Slovak M. L., Willman C. L., Godwin J. E., et al. 2006. Age and acute myeloid leukemia. Blood 107:3481–3485.
    1. Thein, M. S. , Ershler W. B., Jemal A., Yates J. W., and Baer M. R.. 2013. Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer 119:2720–2727.
    1. Peyrade, F. , Gastaud L., Re D., Pacquelet‐Cheli S., and Thyss A.. 2012. Treatment decisions for elderly patients with haematological malignancies: a dilemma. Lancet Oncol. 13:e344–e352.
    1. Rosko, A. , and Artz A.. 2017. Reprint of: aging: treating the older patient. Biol. Blood Marrow Transplant. 23(3s):S10–S17.
    1. Oran, B. , and Weisdorf D. J.. 2012. Survival for older patients with acute myeloid leukemia: a population‐based study. Haematologica 97:1916–1924.
    1. Lowenberg, B. , Ossenkoppele G. J., van Putten W., Schouten H. C., Graux C., Ferrant A., et al. 2009. High‐dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 361:1235–1248.
    1. Surveillance E, and End Results (SEER) Program () SEER*Stat Database. Incidence ‐ SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2016 Sub (1973‐2014 varying) ‐ Linked To County Attributes ‐ Total U.S., 1969‐2015 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2017, based on the November 2016 submission.
    1. Surveillance E, and End Results (SEER) Program () SEER*Stat Database. Incidence ‐ SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (1973‐2013 varying) ‐ Linked To County Attributes ‐ Total U.S., 1969‐2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission.
    1. Surveillance E, and End Results (SEER) Program () SEER*Stat Database. Incidence ‐ SEER 9 Regs Research Data, Nov 2016 Sub (1973‐2014) <Katrina/Rita Population Adjustment> ‐ Linked To County Attributes ‐ Total U.S., 1969‐2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2017, based on the November 2016 submission.
    1. Schiffer, C. A. 2010. “I am older, not elderly”, said the patient with acute myeloid leukemia. J. Clin. Oncol. 28:521–523.
    1. Wildes, T. M. , Rosko A., and Tuchman S. A.. 2014. Multiple myeloma in the older adult: better prospects, more challenges. J. Clin. Oncol. 32:2531–2540.
    1. Thomas, X. , and Le Jeune C.. 2017. Treatment of elderly patients with acute myeloid leukemia. Curr. Treat. Options Oncol. 18:2.
    1. Buchner, T. , Berdel W. E., Haferlach C., Haferlach T., Schnittger S., Muller‐Tidow C., et al. 2009. Age‐related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J. Clin. Oncol. 27:61–69.
    1. Frohling, S. , Schlenk R. F., Kayser S., Morhardt M., Benner A., Dohner K., et al. 2006. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98‐B. Blood 108:3280–3288.
    1. Farag, S. S. , Archer K. J., Mrozek K., Ruppert A. S., Carroll A. J., Vardiman J. W., et al. 2006. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long‐term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 108:63–73.
    1. Kantarjian, H. , Ravandi F., O'Brien S., Cortes J., Faderl S., Garcia‐Manero G., et al. 2010. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116:4422–4429.
    1. Hamaker, M. E. , Stauder R., and van Munster B. C.. 2014. Exclusion of older patients from ongoing clinical trials for hematological malignancies: an evaluation of the national institutes of health clinical trial registry. Oncologist 19:1069–1075.
    1. Dechartres, A. , Chevret S., Lambert J., Calvo F., and Levy V.. 2011. Inclusion of patients with acute leukemia in clinical trials: a prospective multicenter survey of 1066 cases. Ann. Oncol. 22:224–233.
    1. Palumbo, A. , and Anderson K.. 2011. Multiple myeloma. N. Engl. J. Med. 364:1046–1060.
    1. Kumar, S. K. , Dispenzieri A., Lacy M. Q., Gertz M. A., Buadi F. K., Pandey S., et al. 2014. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122–1128.
    1. Warren, J. L. , Harlan L. C., Stevens J., Little R. F., and Abel G. A.. 2013. Multiple myeloma treatment transformed: a population‐based study of changes in initial management approaches in the United States. J. Clin. Oncol. 31:1984–1989.
    1. Evens, A. M. , Helenowski I., Ramsdale E., Nabhan C., Karmali R., Hanson B., et al. 2012. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 119:692–695.
    1. Project TIN‐HsLPF 1993. A predictive model for aggressive non‐hodgkin's lymphoma. N. Engl. J. Med. 329:987–994.
    1. The Non‐Hodgkin’s Lymphoma Project . 1997. Effect of age on the characteristics and clinical behavior of non‐Hodgkin's lymphoma patients.. Ann. Oncol. 8:973–978.
    1. Thieblemont, C. , Grossoeuvre A., Houot R., Broussais‐Guillaumont F., Salles G., Traulle C., et al. 2008. Non‐Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann. Oncol. 19:774–779.
    1. Scher, K. S. , and Hurria A.. 2012. Under‐representation of older adults in cancer registration trials: known problem, little progress. J. Clin. Oncol. 30:2036–2038.
    1. Mareschal, S. , Lanic H., Ruminy P., Bastard C., Tilly H., and Jardin F.. 2011. The proportion of activated B‐cell like subtype among de novo diffuse large B‐cell lymphoma increases with age. Haematologica 96:1888–1890.
    1. Park, S. , Lee J., Ko Y. H., Han A., Jun H. J., Lee S. C., et al. 2007. The impact of Epstein‐Barr virus status on clinical outcome in diffuse large B‐cell lymphoma. Blood 110:972–978.
    1. Glaser, S. L. , Lin R. J., Stewart S. L., Ambinder R. F., Jarrett R. F., Brousset P., et al. 1997. Epstein‐Barr virus‐associated Hodgkin's disease: epidemiologic characteristics in international data. Int. J. Cancer 70:375–382.
    1. Stark, G. L. , Wood K. M., Jack F., Angus B., Proctor S. J., Taylor P. R., et al. 2002. Hodgkin's disease in the elderly: a population‐based study. Br. J. Haematol. 119:432–440.
    1. Roy, P. , Vaughan Hudson G., Vaughan Hudson B., Esteve J., and Swerdlow A. J.. 2000. Long‐term survival in Hodgkin's disease patients. A comparison of relative survival in patients in trials and those recorded in population‐based cancer registries. Eur. J. Cancer 36:384–389.
    1. Gopal, A. K. , Bartlett N. L., Forero‐Torres A., A. Younes , Chen R., Friedberg J. W., et al. 2014. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30‐positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk. Lymphoma 55:2328–2334.
    1. Forero‐Torres, A. , Holkova B., Goldschmidt J., Chen R., Olsen G., Boccia R. V., et al. 2015. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood 126:2798–2804.
    1. Vose, J. M. , Armitage J. O., Weisenburger D. D., Bierman P. J., Sorensen S., Hutchins M., et al. 1988. The importance of age in survival of patients treated with chemotherapy for aggressive non‐Hodgkin's lymphoma. J. Clin. Oncol. 6:1838–1844.
    1. Bastion, Y. , Blay J. Y., Divine M., Brice P., Bordessoule D., Sebban C., et al. 1997. Elderly patients with aggressive non‐Hodgkin's lymphoma: disease presentation, response to treatment, and survival–a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J. Clin. Oncol. 15:2945–2953.
    1. Pfreundschuh, M. , Schubert J., Ziepert M., Schmits R., Mohren M., Lengfelder E., et al. 2008. Six versus eight cycles of bi‐weekly CHOP‐14 with or without rituximab in elderly patients with aggressive CD20 + B‐cell lymphomas: a randomised controlled trial (RICOVER‐60). Lancet Oncol. 9:105–116.
    1. Coiffier, B. , Thieblemont C., Van Den Neste E., Lepeu G., Plantier I., Castaigne S., et al. 2010. Long‐term outcome of patients in the LNH‐98.5 trial, the first randomized study comparing rituximab‐CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116:2040–2045.
    1. Peyrade, F. , Bologna S., Delwail V., Emile J. F., Pascal L., Ferme C., et al. 2017. Combination of ofatumumab and reduced‐dose CHOP for diffuse large B‐cell lymphomas in patients aged 80 years or older: an open‐label, multicentre, single‐arm, phase 2 trial from the LYSA group. Lancet Haematol. 4:e46–e55.
    1. Peyrade, F. , Jardin F., Thieblemont C., Thyss A., Emile J. F., Castaigne S., et al. 2011. Attenuated immunochemotherapy regimen (R‐miniCHOP) in elderly patients older than 80 years with diffuse large B‐cell lymphoma: a multicentre, single‐arm, phase 2 trial. Lancet Oncol. 12:460–468.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe